Last edited by Shaktimi
Saturday, August 1, 2020 | History

4 edition of Characterization of mice with a null mutation in the glucagon-like peptide-1 receptro gene found in the catalog.

Characterization of mice with a null mutation in the glucagon-like peptide-1 receptro gene

Sonya M. Cook

Characterization of mice with a null mutation in the glucagon-like peptide-1 receptro gene

by Sonya M. Cook

  • 150 Want to read
  • 18 Currently reading

Published by National Library of Canada in Ottawa .
Written in English


Edition Notes

Thesis (M.Sc.) -- University of Toronto, 1998.

SeriesCanadian theses = -- Thèses canadiennes
The Physical Object
FormatMicroform
Pagination2 microfiches : negative. --
ID Numbers
Open LibraryOL20234908M
ISBN 100612408027
OCLC/WorldCa51448021

Exendin-4, an FDA-approved antidiabetic glucagon-like peptide 1 (GLP-1) receptor agonist, has been tested in mice with the mutated human huntingtin protein showing neurodegenerative changes, motor dysfunction, poor energy metabolism, and high blood glucose levels. Exendin-4 (Ex-4) treatment reduced the accumulation of mutated human huntingtin protein aggregates, improved motor function Aliases: GLP1R, entrez, glucagon-like peptide 1 . This missense mutation resulted in a proline to serine change at position 86 in the GCGR protein. The mutation was not found in the patient’s brother or in 28 unrelated United States residents. The intron-exon borders of the patient’s GCGR gene did not harbor mutations that may cause errors in mRNA splicing. The glucagon gene of the patient did not contain mutations in the exons or intron-exon Cited by:

  Salazar I, Vaillant C. Glucagon-like immunoreactivity in hypothalamic neurons of the rat. Cell Tissue Res. Aug; (2)– Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Glucagon‐like peptide‐1 (GLP‐1) was originally identified as a glucagon‐like polypepetide from the glucagon precursor 5. GLP‐1(7‐37) and GLP‐1(7‐36) amide were shown to be released from intestinal L cells, and stimulate insulin secretion from pancreatic β‐cells directly by:

(). Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. (). Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. (). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. (). Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice Article (PDF Available) in Diabetes 58(10) August with Reads How we measure 'reads'.


Share this book
You might also like
Introduction to linear programming

Introduction to linear programming

The credit repair kit

The credit repair kit

Twenty-seventh annual coal report of the Illinois Bureau of Labor Statistics 1908.

Twenty-seventh annual coal report of the Illinois Bureau of Labor Statistics 1908.

Elements of renal physiology

Elements of renal physiology

Air pollution meteorology and chemistry research

Air pollution meteorology and chemistry research

causes and prevention of manganese poisoning

causes and prevention of manganese poisoning

How a woman ages

How a woman ages

White Lilac

White Lilac

A history of Latvia.

A history of Latvia.

Problems in advanced organic chemistry.

Problems in advanced organic chemistry.

Nine plays

Nine plays

truth about the question of Bessarabia.

truth about the question of Bessarabia.

economy of Kenya.

economy of Kenya.

Characterization of mice with a null mutation in the glucagon-like peptide-1 receptro gene by Sonya M. Cook Download PDF EPUB FB2

The monoclonal antibody Glp1R antagonised mouse, human, rat, cynomolgus monkey and dog GLP1R. This antagonistic activity was specific to GLP1R; no antagonistic activity was found in cells overexpressing the glucose-dependent insulinotropic peptide receptor (GIPR), glucagon like peptide-2 receptor or glucagon by: 6.

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene Skip to main content Thank you for visiting by:   Glucagonlike peptide 1 (GLP-1) is a neurotransmitter produced in the brain stem and an incretin hormone released from gut endocrine L cells.

GLP-1 was shown to have a role in central regulating of feeding in rat and human GLP-1–activated brain areas known to regulate food intake ().GLP-1 also has an important role in regulating insulin release through activation of the GLP-1 receptor Cited by: Characterization of mice with a null mutation in the glucagon-like peptide-1 receptor gene.

Sonya M. Cook, Institute of Medical Science, University of Toronto. Master's of Science, Glucagon-like peptide-1 (GLP-I) regulates blood glucose through stimulation of glucose-dependent insulin secretion, inhibition of gastric.

Scrocchi LA, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. ;2(11)– View Cited by: Another cohort of VSG rats with CGM was used to investigate whether the blockade of glucagon-like peptide-1 receptor (GLP-1R) signaling alleviates these symptoms.

Glucagon like peptide-1 (GLP-1) enhances glucose-dependent insulin secretion by binding to GLP-1 receptors (GLP1Rs) on pancreatic beta cells. GLP-1 mimetics are used in the clinic for the treatment of type 2 diabetes, but despite their therapeutic success, several clinical effects of GLP-1 remain unexplained at a mechanistic level, particularly in extrapancreatic by: 6.

LA Scrocchi, TJ Brown, N MaClusky, et e intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat Med, 2 Cited by: Endocri- nology4. Scrocchi LA, Brown TJ, MacLusky N, et al: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Nat Med5. Turton MD, O'Shea D, Gunn I, et al: A role for glucagon-like peptide-1 in the central regulation of by: Newborn mice homozygous for a targeted disruption of insulin-like growth factor gene 1 (Igf-1) exhibit a growth deficiency similar in severity to that prevlously observed in viable Igf-2 null mutants (60% of normal birthweight).

Depending on genetic background, some of the Igf1(−/−) dwarfs die shortly after birth, while others survive and reach by: Salazar I, Vaillant C. Glucagon-like immunoreactivity in hypothalamic neurons of the rat. Cell Tissue Res. Aug; (2)– Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ.

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor by:   Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

Auton. Neurosci.36–43 ().Cited by: Use of GLP-1 receptor cell lines for characterization of the native metabolites of GLP A.L. Joyner, D.J. DruckerGlucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Nat Med, 2 (11) (), pp. Cited by:   Glucagon-like peptide 1 (GLP-1) is a proglucagon-derived peptide secreted from intestinal L-cells in response to nutrient ingestion (1,2). GLP-1 acts as an incretin to lower postprandial glycemic excursion via stimulation of insulin secretion and inhibition of glucagon by: Glucagon-like peptide(7–36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.

Endocrinology Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Nat Med ;– PubMed CrossRef Google Scholar Cited by: 1. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJGlucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat Med, 2 (11) (), pp. Author: Patricia M.

Vuguin, Maureen J. Charron. Scrocchi, L. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2, – ().Cited by: 1. Abstract. The effect of exendin-(9–39), a described antagonist of the glucagon-like peptide-1 (GLP-1) receptor, was evaluated on the formation of cAMP- and glucose-stimulated insulin secretion (GSIS) by the conditionally immortalized murine βTC-Tet by:   Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic α cells in response to low blood glucose.

To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr−/−).

These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared Cited by:.

In this issue of Endocrinology, MacLusky et al. use mice with targeted gene deletion of the glucagon-like-peptide-1 (GLP-1) receptor to study the role of GLP-1 signaling to control a number of neuroendocrine studies highlight the very exciting stage that endocrine and neuroendocrine research has reached.

Recent technical advances, and a decade and a half of Cited by: 5. GLUCAGON-LIKE peptide-1 (GLP-1) produced in the enteroendocrine cells of the small and large intestine is a potent incretin and stimulates both glucose-dependent insulin secretion (1–5) and proinsulin gene expression (6, 7).GLP-1 appears to induce glucose competence in islet β-cells by recruiting glucose-resistantβ -cells, actions that further enhance the capacity for glucose-stimulated Cited by: To elucidate the role of neuropeptide Y (NPY)-Y1 receptor (Y1-R) in food intake, energy expenditure, and other possible functions, we have generated Y1-R-deficient mice (Y1-R-/-) by gene targeting.